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Key Points
• No overall clinical benefit was seen following the addition of Lestaurtinib to standard 
chemotherapy for newly-diagnosed FLT3-mutated AML  
• Lower rates of relapse and improved overall survival were seen in patients who 
achieved sustained levels of FLT3 inhibitory activity 
Abstract
The clinical benefit of adding FLT3-directed small molecule therapy to standard first-line 
treatment of acute myeloid leukemia (AML) has not yet been established. As part of the UK 
AML15 and 17 trials, patients with previously-untreated AML and confirmed FLT3-activating 
mutations, mostly aged <60 years, were randomised to receive oral Lestaurtinib (CEP701), 
or not, following each of four cycles of induction and consolidation chemotherapy. 
Lestaurtinib was commenced 2 days after completing chemotherapy and administered in 
cycles of up to 28 days. The trials ran consecutively; primary endpoints were overall survival 
in AML15 and relapse-free survival in AML17; outcome data were meta-analysed. 500 
patients were randomised between Lestaurtinib and control; 74% had FLT3-ITD mutations, 
23% FLT3-TKD point mutations, 2% both types. No significant differences were seen in 
either 5-year overall survival (Lestaurtinib 46% vs control 45%, HR 0.90 [0.70-1.15], p=0.3) or 
5-year relapse-free survival (40% vs 36%, HR 0.88 [0.69-1.12], p=0.3). Exploratory sub-group 
analysis suggested survival benefit with Lestaurtinib in patients receiving concomitant azole 
anti-fungal prophylaxis and gemtuzumab ozogamicin with the first course of chemotherapy. 
Correlative studies included analysis of in vivo FLT3 inhibition by plasma inhibitory activity 
assay and indicated improved overall survival and significantly reduced rates of relapse in 
Lestaurtinib-treated patients who achieved sustained >85% FLT3 inhibition. In conclusion, 
combining Lestaurtinib with intensive chemotherapy proved feasible in younger patients 
with newly-diagnosed FLT3-mutated AML but yielded no overall clinical benefit. The 
improved clinical outcomes seen in patients achieving sustained FLT3 inhibition encourage 
continued evaluation of FLT3-directed therapy alongside front-line AML treatment. 
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Introduction
Activating mutations of the receptor tyrosine kinase FMS-like tyrosine kinase-3 (FLT3) are 
present at diagnosis in approximately one-third of patients with acute myeloid leukemia 
(AML), the majority of whom have a normal karyotype (1-3). Internal tandem duplication 
(ITD) mutations of the FLT3 juxtamembrane domain account for approximately three-
quarters of these mutations and are associated with proliferative disease phenotype, 
increased relapse rate and shortened overall survival (OS) (4-6). The prognostic 
implications of the FLT3-ITD mutation vary according to mutation burden, with a high allelic 
ratio predicting higher relapse risk (5), and according to presence of co-existing mutations; 
the most frequent of these being NPM1c which is present in 60% of younger FLT3-ITD 
mutated cases and appears to lessen the adverse prognostic impact (7). Tyrosine kinase 
domain point mutations make up the remaining 25%  of FLT3 mutations and have less 
clearly-established prognostic associations (8). 
Given the high incidence and clear deleterious prognostic impact of FLT3-ITD mutations, 
there has been a great deal of clinical interest in FLT3 as a therapeutic target and a number 
of small molecule inhibitors with inhibitory activity against FLT3 have entered clinical trials 
(9). Although many of the patient responses seen in the early FLT3 monotherapy trials were 
limited in both depth and duration (10-14), there have been more recent reports of deeper, 
sustained remissions from newer, more potent FLT3 inhibitory compounds (15;16).  
Lestaurtinib (previously CEP-701), one of the so-called ‘first generation’ of FLT3 inhibitors, is 
an orally-available indolocarbazole alkaloid compound that was identified as a potent 
inhibitor of FLT3 (in both its ITD- and point-mutated configurations) at low nanomolar in 
vitro concentrations (17) after originally being developed as a TrkA neurotropin receptor 
inhibitor(18); it is also a potent inhibitor of JAK2(19;20). Lestaurtinib is orally bioavailable 
and was generally well-tolerated in two monotherapy trials, in relapsed / refractory AML 
patients and in older patients considered unsuitable for intensive therapy, where transient 
clinical responses, characterised by reductions in peripheral blood or bone marrow blasts or 
decreased transfusion requirements, were observed primarily in patients harbouring FLT3-
activating mutations (13;14). Crucially in both of these monotherapy studies, clinical activity 
of Lestaurtinib correlated closely with evidence of achievement of sustained reduction of 
FLT3 phosphorylation by >85%, as determined by plasma inhibitory activity (PIA) assay (21).  
Synergistic cytotoxicity to FLT3-mutated AML cells was observed in the laboratory when 
Lestaurtinib was administered sequentially following chemotherapeutic agents (22). On this 
basis, the combination of Lestaurtinib with chemotherapy (either MEC or high dose AraC) 
was assessed in the Cephalon 204 trial, a randomised phase III study in patients with 
relapsed FLT3-mutated AML (23). Although no significant improvements in second complete 
remission (CR) rate or OS were demonstrated with the addition of Lestaurtinib, correlation 
was again observed between in vivo FLT3 inhibition and achievement of clinical response; 
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however a disappointing proportion Cephalon 204 study patients failed to achieve free drug 
levels sufficient to achieve optimal FLT3 inhibitory activity.  
The published randomised clinical trial experience of FLT3-targeted kinase inhibitors has so 
far been limited to the difficult-to-treat population of AML patients with relapsed or 
refractory disease. The potential clinical benefit of combining FLT3-targeted therapy with 
first-line intensive chemotherapy in patients with previously-untreated AML has not yet 
been formally established. We undertook the first prospective randomised assessment of 
the addition, or not, of oral Lestaurtinib, given sequentially following each cycle of 
chemotherapy, to newly-diagnosed AML patients presenting with a FLT3-ITD or FLT3-TKD 
mutation. This intervention was part of the UK MRC AML15 (ISRNCTN17161961) and carried 
forward, with the data blinded, into the UK NCRI AML17 (ISRNCTN55675535) trial.  
Methods
Study design and participants 
The UK MRC AML15 and NCRI AML 17 studies (ISRCTN 17161961 and 55675535) were large, 
prospective phase 3 multi-centre trials for patients with newly-diagnosed AML or high risk 
myelodysplastic syndrome (MDS) (>10% marrow blasts) which ran consecutively between 
May 2002 and December 2014 at >130 centres in the United Kingdom, Denmark and New 
Zealand and addressed several randomised questions (Supplemental Table 1). During 2007 
to October 2012 patients with a FLT3 mutation could be randomised to Lestaurtinib or not. 
Patients were generally aged <60yrs, although older patients could be entered if considered 
suitable for intensive chemotherapy. Patients with acute promyelocytic leukemia or blast 
transformation of chronic myeloid leukemia were not eligible for randomisation.  
Both trials were sponsored by Cardiff University and approved by Wales REC3 on behalf of 
all UK investigators, by the Danish Medicines Agency for sites in Denmark, and by MEDSAFE 
for sites in New Zealand. The trials were conducted in accordance with the Declaration of 
Helsinki, written consent being required for each randomisation. 
The trial designs of AML15 and AML17 involved a number of randomised interventions 
(Figure 1). Induction chemotherapy (courses 1-2) was with ADE, DA or FLAG-Ida with or 
without gemtuzumab ozogamicin (GO) in course 1; consolidation (courses 3-4) comprised 
high dose cytarabine (1.5g/m2 or 3g/m2) or MACE/MidAC. Allogeneic stem cell 
transplantation was permitted for patients with intermediate- or poor-risk disease with a 
recommendation of myeloablative conditioning for patients aged <35 years and reduced 
intensity conditioning for patients >45 years, with investigator/patient choice in the 
intermediate age group in AML15, but was recommended only for poor risk patients in 
AML17. In neither trial was FLT3 status an indication for transplant.   
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Patients entered the allocated first induction chemotherapy course during which 
investigators were informed of the FLT3 mutation status which was centrally-ascertained for 
all patients in one of two reference labs. Patients confirmed to harbour a FLT3 mutation 
(FLT3 ITD or TKD mutation quantified at ≥5% of total FLT3 alleles) were able to enter the 
Lestaurtinib randomisation and to start the allocated treatment 48 hours after completion 
of course 1 of induction treatment.
Lestaurtinib randomisation and treatment schedule 
In AML15, eligible patients were randomised in a 1:1 ratio to receive Lestaurtinib, or not, 
following each of four courses of chemotherapy. In AML17, this randomisation was placebo 
controlled, with an allocation ratio of 2:1 Lestaurtinib to placebo.  In both studies, treatment 
allocation was by web-based computer minimisation hosted by Cardiff University (Cardiff, 
UK). Minimisation parameters were age (0-15, 16-29, 30-39, 40-49, 50-59, or 60 years and 
older), WHO performance status (0-4), induction treatment and de-novo versus secondary 
disease versus high risk MDS.  
Lestaurtinib (Cephalon Inc, Frazer, PA) was commenced 2 days after completion of each 
course of chemotherapy and administered in cycles of up to 28 days for a maximum of 4 
cycles, being stopped at least 2 days before commencing the next course of chemotherapy 
(Figure 1). The initial dose was 80mg orally twice daily (bd) (12 hours between doses); if 
well-tolerated an increase to a maximum dose of 100mg bd was permitted from cycle 2 
onwards. In case of additional toxicity, which was anticipated with the co-administration of 
azole anti-fungal drugs (which have CYP3A4 inhibitory activity), provision was made for a 
reduced dose of 40-60mg bd. There was no maintenance therapy with Lestaurtinib. Patients 
receiving allogeneic stem cell transplant continued Lestaurtinib until 28 days after their last 
pre-transplant course of chemotherapy but did not receive further Lestaurtinib following 
transplant.  
Correlative Studies 
Whole-blood samples were requested to be sent to the central UK lab on day 14 (+/- 2 days) 
of each cycle of Lestaurtinib. The samples were to be taken 12 hours after the patient’s 
most recent dose, to enable assessment of trough FLT3 plasma inhibitory activity (PIA), 
trough plasma concentration of Lestaurtinib and FLT3 ligand (FL) levels. Samples were 
separated by centrifugation and plasma stored frozen at -80°C before batch shipment.  
The PIA assay was performed at Johns Hopkins University, Baltimore, MD as previously 
described (21). Briefly, frozen plasma samples were thawed and clarified by centrifugation 
at 16,000g for 2 minutes. For each time point, 2 x 106 TF/ITD cells (human AML TF-1 cell line 
expressing a FLT3-ITD construct) were incubated with 1ml patient plasma at 37°C for 1 hour. 
Cells were then washed twice with ice-cold phosphate-buffered saline and lysed. After 
immunoblotting for phosphorylated FLT3, densitometric analysis was performed and the 
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FLT3 PIA for each plasma sample was calculated by expressing the density of its 
corresponding band as a percentage of that obtained from baseline untreated plasma.  
Day 14 trough plasma concentrations of Lestaurtinib were quantified by Cephalon Inc., West 
Chester, PA, using a validated high-performance liquid chromatography method as 
previously described (23).  FL concentrations in plasma samples were determined using an 
ELISA kit obtained from R&D Systems (Minneapolis, US).  
Statistical Analysis
All study endpoints were defined according to the Revised International Working Group 
Criteria (24). The primary outcome measure for the AML15 trial was OS which was amended 
to Relapse Free Survival (RFS) when the randomisation rolled over into AML17.  Secondary 
endpoints were achievement of CR, CR with incomplete peripheral blood count recovery 
(CRi), OS from Lestaurtinib randomisation, relapse and death in remission (for patients 
achieving either CR or CRi), together with haematological recovery times, toxicity (scored 
using the National Cancer Institute Common Toxicity Criteria Version 3.0 (25)) and resource 
usage.  Remission status was determined locally in participating centres.  
All analyses are by intention-to-treat. Categorical endpoints (e.g. CR rates) were compared 
using Mantel-Haenszel tests to give Peto odds ratios and confidence intervals. 
Continuous/scale variables were analysed by non-parametric (Wilcoxon rank sum) tests. 
Time-to-event outcomes were analysed using the log-rank test, with Kaplan-Meier survival 
curves. Odds/hazard ratios (OR/HR) <1 indicate benefit for Lestaurtinib. All survival 
percentages are at 5 years unless otherwise stated. Because of the change of design 
between AML15 and AML17, the two trials have been meta-analysed using standard 
methodology (26) and meta-analytic survival curves plotted. 
In addition to overall analyses, exploratory analyses were performed stratified by the 
randomisation stratification parameters and other important variables, with suitable tests 
for interaction. Because of the well-known dangers of subgroup analysis, these were 
interpreted cautiously.  
Analyses of correlative laboratory studies were carried out using logrank tests and Cox 
proportional hazards regression for multivariable analyses. Repeated measures analyses 
were carried out using multilevel models repeated measure analyses. 
Follow-up is complete until 1st March 2015, with a median follow-up for survival of 50.5 




Between January 2007 and January 2009, 967 adult non-APL patients entered the AML15 
trial and were eligible for FLT3 testing of whom 215 had a FLT3 mutation (ITD alone n=156, 
TKD point mutation alone n=45, both n=3; mutation type undetermined n=7). Between April 
2009 and October 2012, 1708 patients entered AML17, of whom 406 were identified as 
having a FLT3 mutation (ITD alone n=297, TKD alone n=94, both n=12; mutation type 
undetermined n=3). In total, 500 FLT3 mutated patients (AML15 n=175, AML17 n=325; 370 
(74%) who had ITD alone, 115 (23%) with TKD alone and 11 (2%) who had both; median ITD 
mutant percentage 30.9%; range 3-98.4; 57 patients with allelic ratio ≥50%) entered the 
randomisation; 4 patients the mutation type was not determined; for 2 patient the ITD 
allelic ratio was found to be <5% but theseare included in the above. . The characteristics of 
patients which were balanced between the arms, are shown in Table 1. The median age of 
FLT3-randomised patients was 49 years (range 5-68); 5 patients aged below 16 years were 
included. 94% of patients had de novo AML, 5% secondary AML and 1% high risk MDS. The 
majority of patients (89%) had cytogenetically intermediate risk disease with 6% favourable 
and 5% adverse risk. Median presenting WBC was 28 x 109/l (range 0.2-363). 270 patients 
(54%) had concomitant mutated NPM1c. All disease characteristics were balanced between 
Lestaurtinib and control arms as were the other treatment interventions. 
The disposition of the patients is shown in Figure 2. 
Overall Response 
Patients received a median of 3 cycles of Lestaurtinib (range 0-4). With median follow-up of 
50.5 months (range 1.3-97.8) 5-year OS is 45% for all patients randomised: outcomes were 
stratified by treatment arm and trial and are summarised in Table 2. There was no overall 
difference in remission rate (combined CR/CRi at any time) between treatment arms 
(Lestaurtinib 92%, control 94%, OR 1.37 (0.68-2.78), p=0.4).  
Relapse Free and Overall Survival 
No significant differences were seen in either 5-year RFS (Lestaurtinib 40% vs Control 36%, 
HR 0.88 (0.69-1.12), p=0.3) or OS (Lestaurtinib 46% vs Control 45%, HR 0.90 (0.70-1.15), 
p=0.3) (Figure 3). Analyses stratified by trial (AML15 vs 17) showed no heterogeneity of 
effect of Lestaurtinib on any endpoint (Figure 3, Table 2). 
Transplant 
A total of 226 (45%) patients received a stem cell transplant (45% in each arm) at some 
stage, with 198 of these being allografts (control 42%, Lestaurtinib 38%), and 122 allografts 
being delivered in first remission (25% vs 24%) (Table 1). Censoring survival at the time of 
stem cell transplant did not materially change the results (HR 0.92 [0.67-1.25] p=0.6) (Figure 
3a). 
Safety and toxicity 
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Overall, across AML15 and 17, only marginal differences in toxicity were seen between the 
Lestaurtinib and control arms and there was no significant difference in early (30-day or 60-
day) mortality (Supplemental Figure 1). There were moderate increases in nausea and 
diarrhoea with Lestaurtinib in the first two courses of treatment and a slightly higher grade 
of bilirubin in course 1. More antibiotics were required by Lestaurtinib-treated patients in 
courses 1 and 2 and there were also slightly higher supportive care needs during course 2, 
associated with a 2-day increase in median time to platelet recovery (p=0.01) 
(Supplemental Table 2, Supplemental Figure 1). In the AML17 study, where comparisons 
could be made, no significant differences were noted between compliance with Lestaurtinib 
(91%) and placebo (95%) therapy during course 1.
Exploratory Sub-group Analysis 
Exploratory sub-group analyses were performed by age, sex, diagnosis (de novo / secondary 
/ MDS), cytogenetics, risk group, performance status, type of FLT3 mutation, FLT3 mutant 
allelic burden and NPM1 mutation status. No significant interactions were found 
(Supplemental Figure 2), so we explored potential interaction with treatments in the trial 
including  the use of concomitant anti-fungal prophylaxis (Figure 4a) and with the individual 
azole drugs (fluconazole, itraconazole, posaconazole or voriconazole) (Figure 4b). We noted 
that although there was no significant interaction with azole therapy, there appeared to be 
a significantly superior survival in recipients of Lestaurtinib who were on azole prophylaxis 
(HR 0.57 (0.36-0.92), p=0.02; this appears to be due to better survival following relapse for 
which there is no obvious explanation; there was no evidence of azole-related reduction in 
relapse itself or benefit on CR rate. No other significant treatment interactions were seen, 
and in particular, the type of azole prophylaxis did not seem to affect the benefit, although 
for patients in the AML17 trial who received both gemtuzumab ozogamicin (GO) and an 
azole, the addition of Lestaurtinib provided additional benefit (Figure 4c), which resulted 
from a combination of a non-significant reduction in relapse (HR 0.62 (0.35-1.12) p=0.11) 
and significantly better survival post relapse (HR 0.49 (0.25-0.97) p=0.04).
Correlative pharmacodynamic / pharmacokinetic studies 
To estimate the degree of FLT3 inhibition achieved in vivo, trough FLT3 plasma inhibitory 
activity (PIA) was measured at day 14 of each cycle of Lestaurtinib. The PIA assay utilises 
FLT3-dependent cell line TF1-ITD as a ‘surrogate tissue’, allowing FLT3-inhibitory activity 
to be assessed after clearance of leukemia cells from the blood/marrow.  It has previously 
been hypothesised, based on data from pre-clinical and early phase monotherapy studies of 
Lestaurtinib, that sustained inhibition of FLT3 phosphorylation by more than 85% (i.e. to less 
than 15% of its baseline activity) is required in order to achieve a cytotoxic, and clinically-
relevant, response to the drug.11,12
Plasma inhibitory assays at trough were carried out on 83 patients, at a total of 161 
timepoints; a FLT3 PIA of >85% was seen at 118/161 (73%) of all evaluated time points. 82% 
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of the patients (68/83) achieved at least one FLT3 PIA measurement in excess of 85%, with 
64% (53/83) showing >85% inhibition at all assayed timepoints. Although no relationship 
was seen between FLT3 PIA and the successful induction of remission, rates of relapse were 
significantly lower in patients who achieved sustained FLT3 inhibition (FLT3 PIA >85% at all 
evaluated time points) (43% in inhibited vs 68% in non-inhibited patients, HR 0.44 (0.23-
0.86) p=0.02, Figure 5A) leading to a significantly better OS (60% vs 33%, HR 0.50 (0.26-0.97) 
p=0.04, Figure 5B). Although FLT3 inhibition appeared to be greater in patients with NPM1c
mutations (81% vs 39% inhibited, p=0.003) the relationship between PIA and clinical 
outcome remained significant after adjusting for NPM1 mutation status.  Although there 
was some evidence of a beneficial effect of co-administration of azoles on survival, this was 
attributable to better post-relapse survival rather than relapse itself, and was not explained 
by a difference in the PIA levels in azole treated patients (44/64 inhibited with concomitant 
azole; 13/18 inhibited without p=0.8). Day 14 trough plasma Lestaurtinib levels were 
measured in 155 patients after course 1. The median plasma level of Lestaurtinib in course 1 
was 3996ng/ml. Patients who were inhibited according to the FLT3 PIA tended to have 
higher levels of Lestaurtinib during course 1 (median 5663 ng/ml vs 3092 ng/ml p=0.002).  
Among the 83 patients where PIA measurements were carried out, mean day 14 FLT3 ligand 
(FL) concentrations rose through successive courses of Lestaurtinib treatment from 
496pg/ml during course 1 to 1467pg/ml, 2565pg/ml and 2720pg/ml during courses 2, 3 and 
4 (p<.0001 by repeated measures analysis). Despite these rising FL levels, no apparent fall 
off in the proportion of patients successfully achieving optimal levels of FLT3 inhibition was 
observed; a day 14 FLT3 PIA level in excess of 85% was achieved in 73% of assayed patients 
during course 1 (47/64), 76% during course 2 (38/50), 80% during course 3 (24/30) and 53% 
during course 4 (9/17). Additionally, no significant correlation was seen between PIA values 
and FL concentrations in a repeated measures analysis across all time points (p=0.14). 
Discussion
In this prospective randomised assessment, we sought to establish whether the FLT3-
targeted inhibitor Lestaurtinib, added sequentially to standard front-line chemotherapy, 
would improve the clinical outcome for newly-diagnosed younger AML patients with FLT3-
mutated disease. By intention-to-treat analysis, no statistically significant evidence of 
benefit was seen: Lestaurtinib failed to reach its primary endpoints of improving OS or RFS, 
there was no improvement in remission rate or evidence of sub-group benefit restricted 
according to type of FLT3 mutation, FLT3-ITD mutant allelic burden or accompanying NPM1
mutation. Unplanned sub-group analysis did suggest potential benefit with Lestaurtinib 
when combined with azoles and GO in induction. 
In the wider context of FLT3-directed therapy, the most encouraging aspect of our results 
was the demonstration that achievement of sustained levels of in vivo FLT3 inhibition, 
10 
quantified using the FLT3 PIA assay, correlated with significantly improved patient outcome 
in terms of reduced relapse rate and improved OS; these findings augment those of the 
Cephalon 204 trial in which 39% of relapsed FLT3-AML patients with >85% FLT3 inhibition 
during their first course of Lestaurtinib plus chemotherapy achieved a second CR compared 
to only 9% of sub-optimally-inhibited patients (23). Such data appear to re-emphasise the 
validity of FLT3 as a therapeutic target in previously-untreated and relapsed AML, but 
underline that Lestaurtinib is unlikely to be the best drug for future clinical exploitation. 
Although the number of patients with a full set of assays is limited, 27% of assayed 
AML15/17 cases (compared to 42% in Cephalon 204) failed to maintain adequate sustained 
FLT3 inhibition and, as in that trial, large inter-patient variations were observed in steady 
state plasma Lestaurtinib concentrations. We were unable to explain the observed azole 
benefit in terms of any impact of azoles on PIA levels. Lestaurtinib is known to be highly 
plasma protein-bound; it has previously been suggested that levels of free, biologically-
active drug fall as levels of plasma proteins rise during chemotherapy (23). This combination 
of pharmacokinetic limitations make it unlikely to be possible to dose Lestaurtinib in a 
schedule that delivers sustained FLT3 inhibition while maintaining tolerability.   
Progressively rising levels of FLT3 ligand (FL), measured as patients with relapsed AML 
receive chemotherapy, but seemingly independent of FLT3 inhibitor exposure, have been 
hypothesised as one mechanism of resistance to FLT3 inhibition; adding FL to in vitro assays 
significantly blunted the efficacy of a panel of FLT3 inhibitors against cell lines and primary 
AML blasts (27).  In AML15/17, we demonstrated that rising FL levels, again evident as 
patients progressed through chemotherapy, failed to impede target inhibition; no fall off 
was seen in the proportion of patients achieving adequate FLT3 PIA through successive 
treatment cycles, no inverse correlation was observed between FL concentration and FLT3 
PIA and there was no association between FL level and clinical outcome These data 
provide encouragement that rising FL levels may not prove an insurmountable obstacle to 
successful combination of FLT3 inhibition with chemotherapy. 
The clinical benefit seen in the azole recipients may reflect the general benefit of azole 
therapy in AML treatment although we saw no difference in  30- and 60-day mortality with 
azole treatment. The additional clinical benefit observed with the concomitant use of GO in 
induction is especially interesting in the context of our recently-published extended follow-
up data from AML17 which identified FLT3-ITD patients as the only sub-group to benefit 
from increasing course 1 daunorubicin dose from 60 to 90mg/m2; late benefits were seen in 
terms of relapse reduction and improved RFS and OS (28). This potential benefit of 
intensified induction therapy in FLT3-ITD cases was also highlighted in extended follow-up 
data from the ECOG E1900 study (29) . 
Over the period of recruitment of AML15/17, another large, international study, RATIFY, has 
prospectively assessed the addition of ‘first generation’ FLT3-targeted TKI therapy to 
standard chemotherapy in a broadly similar population of younger adults with newly-
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diagnosed FLT3-mutated AML. Midostaurin (PKC412) is an indolocarbazole compound that 
has considerable structural homology with Lestaurtinib and an inhibitory profile that 
includes FLT3, c-KIT, PDGFR-B, VEGFR-2 and protein kinase C. In contrast to AML15/17, 
results of the RATIFY study, published to date in abstract form, point to improvement in 
both OS and EFS in Midostaurin-treated patients (51% vs 43% 5-year OS, p=0.007) (30). In 
the absence of any correlative in vivo data from RATIFY to suggest differences in the degrees 
of FLT3 inhibition achieved by Midostaurin and Lestaurtinib, the reasons for the apparent 
discrepancies in clinical outcome between the studies remain a matter of speculation; the 
incorporation of maintenance FLT3 inhibition upon completion of chemotherapy in RATIFY 
(not permitted in AML15/17) could be relevant as could the greater proportion of patients 
receiving allogeneic SCT in RATIFY (57% versus 43% in AML15/17), or the differences in ‘non-
FLT3’ kinase inhibitory profiles of the compounds. Certainly the incorporation of formal 
prospective randomised assessment of the value of maintenance FLT3-directed therapy, 
including post-transplant, will be pertinent to the design of future ‘FLT3 inhibitor plus 
chemotherapy’ studies. 
The longer term future of this ‘first generation’ of FLT3 inhibitors, relatively non-selective 
compounds that were originally developed to target other kinases, is uncertain. Over the 
lifetime of the AML15/17 study a second generation of  more selective FLT3 inhibitors with 
more restricted ‘off target’ activity and the apparent capability of achieving sustained 
profound FLT3 inhibition in a tolerable fashion, have achieved deeper, longer-lasting 
remissions in the setting of monotherapy of relapsed / refractory FLT3-AML (15;16), and are 
moving into combination with chemotherapy. Differences are well documented between 
the biology of FLT3/ITD AML at initial diagnosis and at relapse, however. In vitro data 
support that, whereas relapsed FLT3-driven disease may be particularly vulnerable to highly-
selective FLT3 inhibition due to the impact of higher FLT3 mutant allelic burden and greater 
‘addiction’ to FLT3 signalling, contrastingly, at the time of initial AML diagnosis, there is far 
less ‘FLT3-dependency’ and selective inhibition of FLT3 alone is usually insufficient to induce 
in vitro cytotoxicity (31). Continuing exploration of the role of multi-kinase inhibition may 
still, therefore, be biologically justified in the setting of newly-diagnosed FLT3-mutated AML. 
The mixed clinical experiences with Lestaurtinib in AML15/17 have, however, re-emphasised 
the necessity of optimising pharmacokinetics when combining kinase inhibition with 
chemotherapy and underlined the importance of continuing to correlate clinical response 
with laboratory evidence of target inhibition in future studies. 
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Table 1: Patient Characteristics. 
AML15 AML17 
Lestaurtinib Control Lestaurtinib Placebo 
Number randomised 88 87 212 113
Age group 
(years)
0-15 0 0 3 2
16-29 9 10 22 10
30-39 15 14 20 10
40-49 24 26 57 31
50-59 30 28 83 44
60+    10 9 27 16
Median (range) 48 (16-66) 46 (16-65) 50 (5-68) 50 (6-65)
Gender Female 47 51 113 57
Male 41 36 99 56
Type of disease de Novo 84 84 198 104
Secondary 3 4 10 6
High risk MDS 0 0 4 3
Performance 
status**
0 54 51 127 64
1 30 31 69 38
2 3 2 10 6
3 1 3 5 4
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* includes people who were not eligible for GO in AML17 and two patients mistakenly originally 
believed to be APL; ** 2 children did not complete the WHO performance status 
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Table 2: Outcomes post Lestaurtinib Randomisation 








Control HR/OR, 95% CI p-value Lestaurti
nib 
Placebo HR/OR, 95%CI p-value
ORR (CR+CRi) 91% 92% 1.14 (0.40-3.28) 0.8 93% 96% 1.58 (0.61-4.08) 0.3 1.37 (0.67-2.77) p=0.4 0.7
30d mortality 3% 2% 1.50 (0.26-8.63) 0.7 1% 0% 4.64 (0.43-49.9) 0.2 2.23 (0.54-9.14) p=0.3 0.5
60d mortality 5% 3% 1.34 (0.30-5.88) 0.7 3% 0% 4.67 (0.87-25.0) 0.07 2.31 (0.76-7.02) p=0.1 0.3
5yr OS 43% 41% 0.93 (0.63-1.38) 0.7 50% 45% 0.88 (0.64-1.21) 0.4 0.90 (0.70-1.15) p=0.4 0.8
5yr OS censored at 
SCT 
51% 41% 0.80 (0.48-1.33) 0.4 53% 47% 0.99 (0.67-1.47) 1.0 0.92 (0.67-1.25) p=0.6 0.5
5 yr CIR 50% 50% 0.98 (0.63-1.15) 0.9 52% 62% 0.79 (0.57-1.09) 0.15 0.85 (0.66-1.10); p=0.2 0.4
5 yr CIDCR 10% 14% 0.70 (0.28-1.71) 0.4 9% 5% 1.78 (0.69-4.57) 0.2 1.08 (0.58-2.03) p=0.8 0.18
5 year RFS 40% 36% 0.92 (0.62-1.36) 0.7 39% 34% 0.85 (0.64-1.16) 0.3 0.88 (0.69-1.12) p=0.3 0.8
CR – complete remission; CRi – complete remission with incomplete count recovery; OS – overall survival; SCT – stem cell transplant; CIR – 
cumulative incidence of relapse; CIDCR – cumulative incidence of death in remission; RFS – relapse free survival.
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Figure 1: Trial designs and treatment plan. A) AML15 (2007-9); B) AML17 (2009-11); C) 
AML17 (2011-14); D) Lestaurtinib treatment schedule 
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Figure 2: CONSORT Diagram 
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Figure 3: Outcomes by treatment. A) Forest plot stratified by trial; B) Overall Survival; C) Relapse Free Survival 
A) 
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Figure 4. Interaction with azole prophylaxis in AML17. A) Azole vs not; B) by type of 
azole; C) survival in patients given concomitant GO and azoles 
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Figure 5: Analysis by Plasma Inhibition. A) Cumulative Incidence of Relapse; B) 
Overall Survival 
